JAMA Network Home
Sign In
Viewpoint

The Case for More Aggressive Masking in Psychedelic Trials

JAMA Psychiatry 10.1001/jamapsychiatry.2026.2858

September 16, 2026 at 11:00 AM EDT

Read the full article

This Viewpoint discusses the UMBRAA (unidentifiable multidrug blinding with reduced, authorized awareness) strategy to address the masking problem in psychedelic trials.

Corresponding Author: Josh D. Woolley, MD, PhD, Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, 675 18th St, San Francisco, CA 94107 (josh.woolley@ucsf.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.2858?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091626

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks